Difficult-to-treat rheumatoid arthritis: what have we learned and what do we still need to learn?

Rheumatology (Oxford) · 2025 · PMC11701314 · PMID 39383505

Europe PMC DOI

hedged sentence

0.2800

closest p · 5.6× alpha

0.2800

boldest claim

The sentences

did not reach statistical significanceP = 0.28not close (p > 0.1)

Vice versa, Novella-Navarro reported concomitant use of MTX in 86% of D2T RA patients categorized as ‘treatment inefficacy’ which was higher than patients with D2T RA due to ‘other’ reason including comorbidities and side-effects (76%), however this difference did not reach statistical significance ( P = 0.28) [ 44 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.